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The objectives of this study were to clone gene that encode filarial SXPI 
protein followed by in vitm expression of the protein. The Special Programme 
for Research and Training in Tropical Diseases (TDR) WHO has advocated 
SXPl as one of the vaccine candidate to curb filarial infection. SXPl antigen 
has been reported to confer protective immunity, causing reduction of 
microfilaraemia levels in jirds (Meriones unguiculatus) blocking subsequent 
Brugia malayi infection. In this study, the gene that encode SXPl antigen was 
517 bp in length and was extracted and amplified from the infective stage (L3) 
of subperiodic Brugia malayi. The gene was successfully cloned into 
replication vector p ~ ~ ~ 2 . 1  (Invitrogen) followed by subcloning into 
mammalian expression vector pVAXl (Invitrogen). The presence of SXPl 
gene in - both vectors were validated by polymerase chain reaction (PCR), 
restriction enzymes analysis (RE) and finally by automated sequencing. The 
cloned SXPl in pVAX was designated as pVAXISXP1. The plasmid bearing 
SXPI gene was transfected into two types of animal cell lines (COS-7 and 
CHO) using Polyfect Transfection Reagent (Qiagen). The successful 
expression of targeted gene in the mammalian cell lines were determined by 
RT-PCR and Western Blotting. The PCR product of the transfected cells was 
517 bp on the agarose gel. In addition, the -20 kDa of expressed SXPl 
protein was detected on nitrocellulose membrane by rabbit polyclonal 
antibody against the SXPI protein. This study has successfully established 
the ground work for future deliberations towards the development of anti- 
brugia transmission blocking genetic vaccine. 
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Objektif kajian ini ialah pengklonan gen yang mengkodkan protein SXPl 
cacing filaria dan seterusnya mengekspresinya secara in vitm. SXPI telah 
dipilih sebagai calun di dalam kajian ini berdasarkan kajian-kajian lepas yang 
menunjukkan keupayaan antigen SXPl memberi perlindungan di dalam 
mengurangkan tahap mikrofilaremia di dalam gerbil (Meriones unguiculatus); 
yang dijangkiti dengan Brugia malayi. Gen SXPl juga dicadangkan oleh TDR 
sebagai calon vaksin bagi mengatasi masalah jangkitan cacing filaria. Gen 
SXPl berberat molekul 517 bp telah dicerakinkan daripada peringkat L3 
Bmgia malayi subperiodik dan seterusnya diamplifikasikan dengan kaedah 
tindakbalas rantai polimerase (PCR). Gen SXPl kemudiannya diklonkan di 
dalam vektor replikasi p ~ ~ ~ 2 . 1  (Invitrogen) dan seterusnya gene SXPl di 
subklonkan di dalam vektor eukariot pVAXl (Invitrogen) untuk proses 
ekspresi protein SXPI. Gen SXPl yang telah diklonkan tadi telah dibuktikan 
kehadirannya dan pada kedudukan yang betul melalui kaedah tindakbalas 
rantai polimerase (PCR), kaedah pencernaan enzim pembatas (RE) dan juga 
melalui kaedah penjujukan gen secara automasi. Bagi membuktikan 
kebolehan gen SXP? di ekspresikan secara in vitro, pVAXlSXP1 telah di 
transfeksikan dengan menggunakan "Polyfect Transfection Reagent" 
(Qiagen) ke atas dua sel haiwan COS-7 dan sel CHO. Kejayaan ekspresi 
protein SXPl telah dibuktikan melalui kaedah tindakbalas rantai polimerase 
berbalik (RT-PCR) dan ini diikuti dengan proses Western Blot. Keputusan 
ujian tindakbalas rantai polimerase menunjukkan gen SXP7 telah 
ditranskripsikan dan ini diikuti dengan keputusan Western Blot yang 
menunjukkan protein SXPl yang mempunyai berberat molekul - 20 kDa telah 
berjaya diekspresikan secara in vitro apabila di probekan menggunakan 
antibodi poliklon terhadap protein SXPl yang dihasilkan di dalam arnab. SXPl 
secara zahirnya tidak lagi diketahui akan sifat kimiawi dan fungsinya, tetapi 
kami percaya dengan kejayaan mengekspresikan protein ini secara in vitro 
merupakan langkah awal di dalam pembangunan vaksin jangkitan yang 
berpunca daripada cacing filaria brugia. 
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CHAPTER l 
INTRODUCTION 
Lymphatic filariasis has existed as a recognizable disorder and it has 
also been recorded since the beginning of human history. Ancient Chinese 
and Indians writings have described this disease as swellings of extremities 
and the genitalia that were highly reminiscent of filarial lesions. Sushruta, the 
Indian physicianlsurgeon in his book, called this disease as slipada (sli 
elephant; pada leg) and also described the prevalence rate was higher in 
individuals living close to stagnant water. Ar Rhazes and Avecenna the two 
famous Persian physicians described this disease in Arabic and Avecenna, 
had reported that the disease was endemic in Alexandria, Egypt. Lymphatic 
filariasis was wrongly diagnosed as leprosy by the Greek physicians. The 
dominant figure in the early history of lymphatic filariasis was Sir Patrick 
Manson, a Scottish physician stationed in China during the second half of the 
nineteenth century. He correctly attributed the profound, deforming swelling of 
the extremities to the infection with filarial parasites. He also demonstrated the 
numerous microfilariae in the blood of a Chinese patient, and described that if 
all the microfilariae were to grow into adult worms, there would be no space 
for any other structure within the human body. He also correctly surmised that 
in order to develop and grow the parasites had to leave the human body 
Lymphatic filariasis is a major cause of clinical morbidity and an 
impediment to socio-economic development (Evans et al., 1993). The disease 
is mosquito-borne and very common in the tropics. The worms that caused 
the infection are Wuchereria bancrofii, Brugia malayi and Brugia timon W. 
bancrofli, the most common filarial parasite, is found in Africa, India, Pacific 
Islands, the Caribbean, South America and South East Asia. Infection due to 
W. bancrofti contributed to 90% of total infections in the tropics and in some 
sub-tropicat areas worfd-wide. In the South East Asia, particutarty in Mataysia, 
13. maiayi is a the main species that caused tymphatic filariasis, and B. timon 
is tirnited to Timor Island and ishnds adjacent to it. In Malaysia, W. b a n m i  is 
mainly found in S a m  and Sarawak. More than 1.2 Miion people, i.e. 20% of 
the wrorki's population live in areas whwe they are at risk of infeetiion, of which 
90% of the infections are with W. bamrdti and 10% with 8. malayi {WHO, 
2000). It is cur~ently estimated that some 512 million people are at risk of 
infection in the sub-Saharan Africa. 
Lymphatic filariasis causes the most debilitating and disfiguring of all 
disease. Lymphatic filariisis has been recognised as one the most prevalent 
of tropical diseases, and the most neglected disease. It afflicts poor people in 
both urban and rural areas. Rarely fatal, it causes extensive disability, gross 
disfigurement and untold suffering for millions: young and old; men, women 
and children. In every community where it occurs, this disease remains a 
strong impediment to socioeconomic development. tymphatic filariasis has 
been identified as among the world's six potentially 'eradicableJ infe&ous 
disease by the International Task Force for Disease Eradication (WHO, t992) 
and was designated as the world's second leading cause of permanent and 
bg  term disability by WHO, The two main strategies are through drug 
therapy and vector control which are going to be implemented toward the 
complete elimination of the disease by the year 2020. 
The development of vaccines for lymphatic filariasis is still in the state 
of relative infancy in comparison to other parasitic diseases such as 
schistosomiasis and malaria. This is due to the complexrty of the filarial 
parasite itself and also due to complex host immune responses, which are 
poorly understood. With the advancement in the field of molecular biology, the 
devetopment of vaccines for lymphatic fitariasis has undergone a new 
dimension. 
Prior studies have shown that a degree of protective immunity to 
filariasis can be induced in animals by vaccination with irradiated l3 ('fate et 
a/., 1985, Weil. .G., et al., 1992). The potential. of using live anti-filariil. 
vaccines in humans is limited because of safety issues and limited availability 
of larvae. Several laboratories are working to develop effective recombinant 
antigen-based vaccines that would be more practical and effective than live 
parasite vaccines. 
DNA vaccination is a promising approach that may have several 
advantages over vaccination with live parasites or protein antigens. DNA 
vaccines have been shown to be an effective means of generating cetlutar 
and humoral immune responses, and they have conferred protection against 
a wide range of infectious agents inctuding viruses, parasites, and bacteria in 
animal models (Montgomery, et a{., 1997). 
0 bjectives 
The general objective of this study is to identify gene that encode filarial 
antigen toward the development of a DNA based vaccine against B. malayi . 
The following are the specific objectives: 
1. To amplify the SXP1 sequence from 8. maiayi. 
2. To clone the amptified SXPl gene into an appropriate vector. 
To express the SXPl protein in vitro after gene transfection in 
mammalian cet t tines. 
CHAPTER l l  
LITERATURE REVIEW 
Lymphatic Filariasis in Malaysia 
Lymphatic filariasis constitutes the principal mosquito-borne nematode 
infection due to three types of filarial worms namely W. bancrofii, B. malayi 
and B. timori. W. bancrofii caused bancroftian filariasis and B. malayi and B. 
timori caused brugian filariasis. Bancroftian filariasis is the more prevalent of 
the two (contribute to 90% of total infections), occurring throughout the tropics 
and subtropics countries; Africa, India, Pacific Islands, the Caribbean, South 
America and Southeast Asia, except Middle East region where infection 
appears to be endemic only in Egypt (Figure 1). In Malaysia, urban 
bancroftian filariasis is unheard of these days, while cases of rural bancroftian 
filariasis have been reported only from Sabah and Sarawak. By contrast, 
bugian filariasis is restricted to South East Asia, including Southern China 
(Figure 2), whereby the B. malayi is the major caused of lymphatic filariasis. 
B. timori is found in Timor Island, Flores and the adjacent islands of 
Indonesia. 
Mak in 1985 was estimated two billion peoples are at risk of infection in 
Malaysia. The predominant species of filarial parasites is subperiodic B. 
malayi which contribute 80.2% of all cases followed by periodic B. malayi 
12.9%, W. bancrofii 5.7% and mixed infection accounts for 1.3% 
